Comprehensive analysis of allergen-specific IgE in COPD: mite-specific IgE specifically related to the diagnosis of asthma-COPD overlap

Table 1 Comparison of patient characteristics between ACO and non-ACO COPD patients

	ACO	Non-ACO COPD	Total	P value
Subject (n)	34	42	76
Sex male (%)	82.4	81.0	81.6	0.88
Body mass index (kg/m²)	24.1 ± 0.6	22.3 ± 0.6	23.1 ± 3.8	0.042*
Age (years)	72.5 ± 1.3	74.3 ± 1.2	73.5 ± 7.6	0.30
Smoking status (current/ex/never [%])	20.6/79.4/0	7.1/90.5/2.4	13.2/85.5/1.3	0.16
Smoking history (pack-years)	55.7 ± 5.8	62.0 ± 5.2	59.2 ± 34.0	0.43
FVC, %predicted	107.6 ± 3.1	105.4 ± 2.8	106.4 ± 17.8	0.59
FEV₁ (L)	1.68 ± 0.12	1.82 ± 0.10	1.76 ± 0.68	0.39
FEV₁, %predicted	72.9 ± 4.1	79.6 ± 3.7	76.6 ± 24.2	0.24
FEV₁/FVC ratio (%)	51.5 ± 2.4	57.1 ± 2.2	54.6 ± 14.1	0.088
RV, % predicted^a	111.2 ± 5.1	112.8 ± 5.0	112.0 ± 27.2	0.82
DLco/V_A, % predicted^b	80.7 ± 5.7	72.6 ± 5.6	76.6 ± 30.9	0.32
Airway reversibility (mL)^c	131.0 ± 23.1	102.9 ± 21.6	116.0 ± 105.6	0.38
Airway reversibility (%)^c	9.3 ± 1.8	5.8 ± 1.7	7.4 ± 8.4	0.16
Blood eosinophil count (cells/μL)	248 ± 29	218 ± 26	231 ± 167	0.45
Serum total IgE (IU/mL)	375 ± 84	258 ± 75	310 ± 488	0.31
FeNO (ppb)^d	33.8 ± 2.6	20.7 ± 2.3	26.4 ± 16.1	< 0.01**
ICS use before diagnosis of ACO (%)	35.3	7.1	19.7	< 0.01**
LABA (%)	85.3	73.8	79.0	0.22
LAMA (%)	82.4	81.0	81.6	0.88
Theophylline (%)	20.6	14.3	17.1	0.47
LTRA (%)	17.7	2.4	9.2	0.022*
Antihistamine (%)	14.7	7.1	10.5	0.29

ACO asthma-COPD overlap, COPD chronic obstructive pulmonary disease, DLco/V_A diffusing capacity of carbon monoxide/alveolar volume, FeNO fraction of exhaled nitric oxide, FEV₁ forced expiratory volume in 1 s, FVC forced vital capacity, ICS inhaled corticosteroid, IgE immunoglobulin E, LABA long-acting β-agonists, LAMA long-acting muscarinic receptor antagonist, RV residual volume, LTRA leukotriene receptor antagonist
^aRV
^bDLco/V_A (ACO n = 29, non-ACO COPD n = 30)
^cAirway reversibility (ACO n = 21, non-ACO COPD n = 24)
^dFeNO (ACO n = 33, non-ACO COPD n = 42)
P < 0.05*, P < 0.01** between ACO and non-ACO COPD groups

ISSN: 1710-1492